Efficacy and safety of hybutimibe on primary hypercholesterolemia: a randomized, double-blinded, placebo and positive–controlled, parallel phase II study-Reference-Cited by-同舟云学术

Efficacy and safety of hybutimibe on primary hypercholesterolemia: a randomized, double-blinded, placebo and positive–controlled, parallel phase II study

Published:2022-04 Issue:2 Volume:7 Page:77-84
ISSN:2470-7511
Container-title:Cardiology Plus
language:en
Short-container-title:

Author:

Qi Litong,Zhao Shuiping,Chen Jiyan,Zhang Mei,Li Xiaodong,Dong Yugang,Guo Xiaomei,Huang Kai,Wang Fang,Huo Yong,Ge Junbo

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference15 articles.

1. Expert recommendations for the prevention and treatment of dyslipidemia in the China Cholesterol Education Program in 2014;Guo;Chin J Heart & Heart Rhythm,2014

2. The second Chinese clinical blood lipid control compliance rate and influencing factors multi-center collaborative study;Chin J Cardiol,2007

3. Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients;Gylling;Atherosclerosis,2002

4. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis;Mikhailidis;Curr Med Res Opin,2011

5. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials;Morrone;Atherosclerosis,2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2023 China Guidelines for Lipid Management;Journal of Geriatric Cardiology;2023-09

2. 2023 Chinese guideline for lipid management;Frontiers in Pharmacology;2023-08-29